FK228 reshapes tumor microenvironment to enhance anti-PD-L1 efficacy
Open Access
- 12 September 2025
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 44 (39) , 3665-3678
Abstract
The lack of a favorable tumor immune microenvironment (TIME) results in limited response rates to immune checkpoint blockade (ICB) across human solid tumors, necessitating the development of novel combination strategies. In this study, we repurposed FK228, an US FDA-approved histone deacetylase inhibitor that is used clinically in non-solid tumor treatment, as a novel ICB sensitizer in solid tumors and revealed the diverse regulatory functions of FK228 in the TIME. FK228 serves as a novel necroptosis inducer in cancer cells by triggering endoplasmic reticulum stress. This in turn enhances the immunogenicity of cancer cells and increases the infiltration of tumor-killing immunocytes, including CD8+ T and natural killer cells, particularly activating tumor-infiltrated CD8+ T cells. Meanwhile, FK228 treatment shifts macrophages toward the pro-inflammatory phenotype. Moreover, the combined use of FK228 and a PD-L1 inhibitor significantly delay tumor growth and extend the survival of tumor bearing mice. Overall, our findings reveal new possibilities for the clinical application of FK228 in solid tumors and underscore the critical role of histone deacetylases in maintaining the immune-unfavorable TIME.Keywords
This publication has 65 references indexed in Scilit:
- Suberanilohydroxamic acid (SAHA), a HDAC inhibitor, suppresses the effect of Treg cells by targeting the c-Myc/CCL1 pathway in glioma stem cells and improves PD-L1 blockade therapyJournal of Neuro-Oncology, 2024
- ELOA promotes tumor growth and metastasis by activating RBP1 in gastric cancerCancer Medicine, 2023
- Nanobody‐Engineered Natural Killer Cell Conjugates for Solid Tumor Adoptive ImmunotherapySmall, 2021
- Cytokine and Epigenetic Regulation of Programmed Death-Ligand 1 in Stem Cell Differentiation and Cancer Cell PlasticityStem Cells, 2021
- Integrated analysis of multimodal single-cell dataCell, 2021
- A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cellsCell, 2021
- An ER‐Targeting Iridium(III) Complex That Induces Immunogenic Cell Death in Non‐Small‐Cell Lung CancerAngewandte Chemie International Edition, 2020
- Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancerCancer Immunology, Immunotherapy, 2020
- Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanismInternational Journal of Cancer, 2014
- Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)Investigational New Drugs, 2008